JP4227195B2 - リポソームインフルエンザワクチンの組成物および方法 - Google Patents

リポソームインフルエンザワクチンの組成物および方法 Download PDF

Info

Publication number
JP4227195B2
JP4227195B2 JP50263298A JP50263298A JP4227195B2 JP 4227195 B2 JP4227195 B2 JP 4227195B2 JP 50263298 A JP50263298 A JP 50263298A JP 50263298 A JP50263298 A JP 50263298A JP 4227195 B2 JP4227195 B2 JP 4227195B2
Authority
JP
Japan
Prior art keywords
composition
liposome
cytokine
csf
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50263298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000513352A5 (enExample
JP2000513352A (ja
Inventor
エリエゼール ケダール，
アイラン ババイ，
エチェケール バレンホルズ，
Original Assignee
イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム filed Critical イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム
Publication of JP2000513352A publication Critical patent/JP2000513352A/ja
Publication of JP2000513352A5 publication Critical patent/JP2000513352A5/ja
Application granted granted Critical
Publication of JP4227195B2 publication Critical patent/JP4227195B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP50263298A 1996-06-24 1997-06-24 リポソームインフルエンザワクチンの組成物および方法 Expired - Fee Related JP4227195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2006396P 1996-06-24 1996-06-24
US60/020,063 1996-06-24
PCT/IL1997/000210 WO1997049423A2 (en) 1996-06-24 1997-06-24 Liposomal influenza vaccine composition and method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008149959A Division JP2008260779A (ja) 1996-06-24 2008-06-06 リポソームインフルエンザワクチンの組成物および方法

Publications (3)

Publication Number Publication Date
JP2000513352A JP2000513352A (ja) 2000-10-10
JP2000513352A5 JP2000513352A5 (enExample) 2005-02-10
JP4227195B2 true JP4227195B2 (ja) 2009-02-18

Family

ID=21796541

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50263298A Expired - Fee Related JP4227195B2 (ja) 1996-06-24 1997-06-24 リポソームインフルエンザワクチンの組成物および方法
JP2008149959A Withdrawn JP2008260779A (ja) 1996-06-24 2008-06-06 リポソームインフルエンザワクチンの組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008149959A Withdrawn JP2008260779A (ja) 1996-06-24 2008-06-06 リポソームインフルエンザワクチンの組成物および方法

Country Status (8)

Country Link
US (1) US5919480A (enExample)
EP (1) EP0954286B1 (enExample)
JP (2) JP4227195B2 (enExample)
AT (1) ATE422352T1 (enExample)
AU (1) AU731705B2 (enExample)
CA (1) CA2258878C (enExample)
DE (1) DE69739253D1 (enExample)
WO (1) WO1997049423A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731972B1 (en) * 2000-02-04 2010-06-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
JP2001521908A (ja) * 1997-10-31 2001-11-13 シストロン バイオテクノロジー インク． ワクチンアジュバントとして有用な封入された免疫調節物質
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
WO2002038175A1 (en) * 2000-11-07 2002-05-16 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
US7662619B2 (en) * 2000-11-15 2010-02-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Sol-fusin: use of GP64-6His to catalyze membrane fusion
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
IL159334A0 (en) * 2001-06-25 2004-06-01 Yissum Res Dev Co A method for preparation of vesicles loaded with biological material and different uses thereof
DE60232413D1 (en) * 2001-07-05 2009-07-02 Ltb4 Sweden Ab Ltb4 als adjuvans für impfstoffe
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
US20040208920A1 (en) * 2002-07-03 2004-10-21 Dov Michaeli Liposomal vaccine
CA2523413A1 (en) 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
WO2004100928A1 (de) * 2003-05-09 2004-11-25 Novosom Ag Injizierbare liposomale depots zum wirkstoffdelivery
EP1666059A4 (en) * 2003-08-11 2008-08-27 Univ Osaka Res Found NEW VACCINE WITH AN ADJUVANS FOR TRIGGERING ABSORBENT IMMUNITY
CN102172397B (zh) * 2003-08-21 2013-01-30 利普泰克有限公司 树突细胞的体内靶向
FR2868951B1 (fr) * 2004-04-15 2006-07-21 Ethypharm Sa Compositions contenant ds vesicules lamellaires incorporant un principe actif peu soluble dans l'eau et produits intermediaires utiles pour leur preparation
US20050260260A1 (en) * 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
WO2006074303A2 (en) * 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
CN106310293A (zh) * 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
EP2231180B1 (en) * 2008-01-16 2016-08-17 Ben-gurion University Of The Negev Research And Development Authority Vaccine for alzheimer's disease
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
AU2009272280B2 (en) * 2008-07-14 2015-08-06 Polypid Ltd. Sustained-release drug carrier composition
EP2391370B1 (en) 2009-02-02 2015-06-03 Galmed Research and Development Ltd. Methods and compositions for treating alzheimer's disease
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
ES2573427T3 (es) 2009-07-06 2016-06-07 Variation Biotechnologies Inc. Procedimientos para preparar vesículas y formulaciones producidas a partir de las mismas
IN2012DN00570A (enExample) 2009-07-14 2015-06-12 Polypid Ltd
AU2010303568B2 (en) * 2009-10-09 2014-07-31 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
CA2783001C (en) 2010-01-19 2017-12-12 Polypid Ltd. Sustained-release nucleic acid matrix compositions
CA2840079C (en) * 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
CN107296792B (zh) 2011-01-13 2021-07-27 变异生物技术公司 囊泡及由其产生之制剂的制备方法
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
CN103998058B (zh) 2011-10-06 2021-11-05 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
EP2780350B1 (en) 2011-11-18 2019-03-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
CN103736090B (zh) * 2014-01-27 2016-03-02 中国医学科学院医学生物学研究所 甲磺酸去铁胺佐剂及含甲磺酸去铁胺佐剂的疫苗
CN110151702A (zh) * 2019-06-24 2019-08-23 昆明医科大学 聚乙二醇修饰流感疫苗脂质体及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
AU627226B2 (en) * 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3037994B2 (ja) * 1989-11-02 2000-05-08 テルモ株式会社 リポソーム表面への蛋白質吸着抑制剤
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JPH07504683A (ja) * 1992-07-08 1995-05-25 シェリング・コーポレーション Ｇｍ−ｃｓｆのワクチンアジュバントとしての利用
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
WO1995004524A1 (en) * 1993-08-06 1995-02-16 Opperbas Holding B.V. A method for high loading of vesicles with biopolymeric substances
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity

Also Published As

Publication number Publication date
EP0954286B1 (en) 2009-02-11
CA2258878C (en) 2008-03-18
WO1997049423A2 (en) 1997-12-31
US5919480A (en) 1999-07-06
AU3188297A (en) 1998-01-14
AU731705B2 (en) 2001-04-05
WO1997049423A3 (en) 1998-02-19
DE69739253D1 (de) 2009-03-26
JP2008260779A (ja) 2008-10-30
EP0954286A2 (en) 1999-11-10
CA2258878A1 (en) 1997-12-31
JP2000513352A (ja) 2000-10-10
ATE422352T1 (de) 2009-02-15

Similar Documents

Publication Publication Date Title
JP4227195B2 (ja) リポソームインフルエンザワクチンの組成物および方法
CA2212382C (en) Cochleate delivery vehicles
AU689505B2 (en) Protein- or peptide-cochleate vaccines and methods of immunizing using the same
Babai et al. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice
JP2005525992A (ja) 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
AU4221489A (en) Affinity associated vaccine
JP2997073B2 (ja) 鼻腔内または吸入投与用ワクチン製剤およびその製造方法
Ben-Yehuda et al. Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents
US20230181711A1 (en) Immunogenic composition comprising an antigenic moiety and a liposomal formulation, method of producing the composition, the composition for use as a medicament, in particular for use as a vaccine
WO1997030725A1 (en) Cochleat delivery vehicles
CN101502649B (zh) 一种脂质体流感疫苗
US20070026005A1 (en) Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
Gregoriadis Liposomes as immunological adjuvants for peptide and protein antigens
BR112012033284B1 (pt) veículo vacinal para induzir resposta imune celular, e, composição vacinal
JPH05339169A (ja) 経口ワクチン
WO2003000232A2 (en) Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides
Gould-Fogerite et al. Cochleate delivery vehicles: applications in vaccine delivery
WO1990001947A1 (en) Affinity associated vaccine
Hampl et al. Effects of Phospholipid Composition on Adjuvant Efficiency of Liposomes
Hussain Formulation and the characterisation of cationic liposomal adjuvants for the delivery of a promising subunit tuberculosis vaccine
AU3259900A (en) Cochleate delivery vehicles
JP2004161781A (ja) 経口ワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070925

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071109

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080606

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20081030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081120

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081128

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111205

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111205

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121205

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees